OncoMatch

OncoMatch/Clinical Trials/NCT06811233

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Is NCT06811233 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including DMSA and Ca-EDTA for acute myeloid leukemia (aml).

Phase 2RecruitingM.D. Anderson Cancer CenterNCT06811233Data as of Jun 2026

Treatment: DMSA · Ca-EDTA · Magnesium Sulfate · MultivitaminThe goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

DMSACa-EDTAMagnesium SulfateMultivitamin

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: bcl2 inhibitor (venetoclax)

Lab requirements

Kidney function

Serum creatinine ≤ 2.0 mg/dL

Liver function

Total Bilirubin ≤ 2.0 x ULN unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) ≤ 2.0 x ULN

Laboratory test results within these ranges (unless due to leukemia or other hematologic malignancy): Serum creatinine ≤ 2.0 mg/dL; Total Bilirubin ≤ 2.0 x ULN unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) ≤ 2.0 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06811233 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior bcl2 inhibitor disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify